Glonghui, May 24 | Shengda Biotech went up and down, while Bonne Group, Kyodo Pharmaceuticals, Fujilai, and Azure Biotech followed suit. According to the news, Beijing released the “Beijing Action Plan to Accelerate Collaborative Innovation in Medicine and Health (2024-2026)”. The “Action Plan” proposes the deployment of “nuclear explosion point” projects in cutting-edge technology fields such as cell-gene therapy, brain-computer interface, and synthetic biology.
A股合成生物概念反弹 圣达生物涨停
The A-share synthetic biology concept rebounded, and Sunda Biotech rose or stopped
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.